# Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT01185821** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 185 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** BAF312

## Key facts

- **NCT ID:** NCT01185821
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-30
- **Primary completion:** 2016-10-10
- **Final completion:** 2016-10-10
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01185821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01185821, "Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01185821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*